Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Product Setback
  5. Clinical Setback

Clinical Setback

Evaluate

Thumbnail
June 07, 2023

Fibrogen’s pamrevlumab fails its first test

Thumbnail
May 25, 2023

Archer misses the target

Annexon’s failure in geographic atrophy could clear the way for its rivals.

Article image
Vantage logo
May 25, 2023

Mirati seeks to shrug off sitravatinib flop

Article image
Vantage logo
May 25, 2023

Normal service resumes in amyotrophic lateral sclerosis

Article image
Vantage logo
May 24, 2023

PTC fails phase 3, and looks to a regulatory filing

Vatiquinone’s pivotal failure in Friedreich’s ataxia prompts a data dredge to come up with a regulatory package. And why not?

Article image
Vantage logo
May 22, 2023

Intercept’s Nash exit feels inevitable

Article image
Vantage logo
April 26, 2023

Tecentriq runs out of luck in triple-negative breast cancer

Roche puts on a brave face as its anti-PD-L1 drug fails yet another TNBC study, this time in the adjuvant setting.

Article image
Vantage logo
April 06, 2023

The Covid crash continues

Pfizer keeps declining, but it is not the only pandemic player to suffer.

Article image
Vantage logo
April 05, 2023

Benevolent AI’s dermatology Trk disappoints

Article image
Vantage logo
April 04, 2023

The cytokine dream sours for Oncosec

Article image
Vantage logo
March 31, 2023

Another ALS failure leaves Cytokinetics reliant on aficamten

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up